Gastric Cancer

Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.

Data from the phase 2 FIGHT study indicated that the monoclonal antibody bemarituzumab may be a promising treatment when combined with mFOLFOX6 for patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

Individuals with nonalcoholic fatty liver disease–related hepatocellular carcinoma were found to have lower rates of surveillance vs other potential causes of disease.

Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.

Prospective data found higher rates of occult signet ring cell gastric cancer among individuals with no family history of gastric cancer but who carried CDH1 P/LP variants.

Laparoscopy compared with open gastrectomy was found to produce better overall survival outcomes at the 5-year follow-up analysis for patients with advanced gastric cancer.

An analysis presented at 2022 IGCC showed that the level of CD8 + cells in the outer margin of gastric cancer tumors was significantly associated with survival outcomes and could inform prognosis.

Men with MSI-high gastric cancer may have shorter overall survival than women, regardless of treatment modality.

Kohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.

Post-resection survival could be predicted by FAM46C expression in patients with gastric adenocarcinoma.

In a presentation at 2022 IGCC, Ju-Seog Lee, PhD, discussed an analysis that combined tumor classification models to derive new prognostic subgroups in gastric cancer.

Laparoscopic proximal gastrectomy led to less vitamin B12 supplement use than total gastrectomy without negatively impacting survival for upper third early gastric cancer.

Adding pembrolizumab to chemotherapy does not improve outcomes over chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to updated results of the KEYNOTE-062 trial.

Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab.

Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.

Research suggests that perioperative S-1 plus oxaliplatin in patients with gastric cancer who have had a D2 gastrectomy yields a clinically significant improvement over adjuvant capecitabine plus oxaliplatin.

Recent data indicated that the combination of neoadjuvant docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 was effective and tolerable in a population of Korean patients who had locally advanced gastric cancer.

The pharmaceutical company plans to voluntarily withdraw the accelerated approval indication for pembrolizumab in the third line setting for patients with gastric cancer within the coming months.

The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.

A combination of trifluridine and tipiracil showed some gains in overall survival for patients with metastatic gastric cancer or gastroesophageal junction cancer.

TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.

Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy. 

Patients responded relatively well to the phase I trial testing a new treatment for several malignancies, including gastric and gastroesophageal junction adenocarcinomas.

A new study found an upward trend over the last 12 years of cases of gastrointestinal cancer in young patients in Latin America.

Dr. Wilson discusses a chemopreventive drug that may help prevent gastric cancer by acting directly on H. pylori.

Researchers tested the novel oral fluoropyrimidine derivative S-1 plus oxaliplatin vs S-1 plus cisplatin in patients with diffuse-type or mixed-type advanced gastric adenocarcinoma.

Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.